UNSPSC 51172174: Fesoterodine fumarate

This classification denotes an anticholinergic agent C26H37NO3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EOS72165S7, chemically known as propanoic acid,2-methyl ,2-((1r)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl ester,(2e)-2-butenedioate (1:1)(salt), but more generally known as fesoterodine fumarate, which bears US NIH Compound Identifier 9849808. Most nations, for tariff and trade purposes, schedule fesoterodine fumarate under HS 29225000 and SITC 51467.

As of Q4 2014, FESOTERODINE FUMARATE remains US FDA's Preferred Term for this commodity. Fesoterodine fumarate bears US NLM NCI C72779. SMILES: CC(C)C(=O)OC1CCC(CC1[C@H](CCN(C(C)C)C(C)C)C2CCCCC2)CO.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51172174 Fesoterodine fumarate is a Commodity code identifying a specific branded or generic urological pharmaceutical, but state and local procurement activity under this code shows minimal direct relevance; recent opportunities tagged to it involve broader pharmaceutical procurement, drug testing services, and pharmacy benefit programs rather than fesoterodine specifically. State and local governments do procure pharmaceuticals through cooperative purchasing vehicles and centralized health benefit programs, and this code may see activity when correctional facilities, health departments, or Medicaid agencies specifically source this drug. However, the recent opportunities block shows only one moderately relevant solicitation—Collin County's offender drug testing RFP—and two tangentially related pharmaceutical-program RFIs and RFPs that do not target fesoterodine as a line item.

Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services with a response date of July 23, 2026, estimated contract value of $600,000, and a two-year initial term commencing September 1, 2026 with three optional one-year renewals. The Texas Health and Human Services Commission posted RFI HHS0017013 on March 27, 2026 (deadline April 3, 2026) exploring direct-to-manufacturer prescription programs without identifying fesoterodine or specific therapeutic categories. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, effective July 1, 2026, and no specific award value disclosed. Geographic activity centers on Texas and Minnesota; no other states appear in the recent-opportunities block. Firms pursuing fesoterodine sales to state and local buyers should monitor correctional-health and Medicaid-managed-care solicitations rather than expect direct demand under this commodity code.